| Outcome of Interest . | N (%) . |
|---|---|
| Treatment regimens required | |
| Multiple treatment regimens | 45 (44) |
| Single treatment regimen | 58 (56) |
| Number of required regimens | |
| 1 | 58 (56) |
| 2 | 26 (25) |
| 3 | 8 (8) |
| 4 | 7 (7) |
| >=5 | 4 (4) |
| Refractory/relapsed OPG by 2 years, N = 100 | 22 (22) |
| Refractory/relapsed OPG by 5 years, N = 90 | 36 (40) |
| Time from initial treatment to second regimen, median (range) | 21.5 months (2-149 months) |
| Indication for second regimen, N = 44 | |
| Decline in visual acuity | 18 (41) |
| Radiographic | 22 (50) |
| Other | 4 (9) |
| Second treatment regimen, N = 44 | |
| Carboplatin/vincristine | 6 (13) |
| Vinblastine | 12 (27) |
| Bevacizumab/irinotecan | 8 (18) |
| Temozolomide | 4 (9) |
| MEK inhibitor | 5 (11) |
| Other | 9 (20) |
| Duration of follow-up, median (range) | 95 months (13-185 months) |
| Outcome of Interest . | N (%) . |
|---|---|
| Treatment regimens required | |
| Multiple treatment regimens | 45 (44) |
| Single treatment regimen | 58 (56) |
| Number of required regimens | |
| 1 | 58 (56) |
| 2 | 26 (25) |
| 3 | 8 (8) |
| 4 | 7 (7) |
| >=5 | 4 (4) |
| Refractory/relapsed OPG by 2 years, N = 100 | 22 (22) |
| Refractory/relapsed OPG by 5 years, N = 90 | 36 (40) |
| Time from initial treatment to second regimen, median (range) | 21.5 months (2-149 months) |
| Indication for second regimen, N = 44 | |
| Decline in visual acuity | 18 (41) |
| Radiographic | 22 (50) |
| Other | 4 (9) |
| Second treatment regimen, N = 44 | |
| Carboplatin/vincristine | 6 (13) |
| Vinblastine | 12 (27) |
| Bevacizumab/irinotecan | 8 (18) |
| Temozolomide | 4 (9) |
| MEK inhibitor | 5 (11) |
| Other | 9 (20) |
| Duration of follow-up, median (range) | 95 months (13-185 months) |
Abbreviations: MEK, mitogen-activated kinase kinase; OPG, optic pathway glioma; VA, visual acuity.
| Outcome of Interest . | N (%) . |
|---|---|
| Treatment regimens required | |
| Multiple treatment regimens | 45 (44) |
| Single treatment regimen | 58 (56) |
| Number of required regimens | |
| 1 | 58 (56) |
| 2 | 26 (25) |
| 3 | 8 (8) |
| 4 | 7 (7) |
| >=5 | 4 (4) |
| Refractory/relapsed OPG by 2 years, N = 100 | 22 (22) |
| Refractory/relapsed OPG by 5 years, N = 90 | 36 (40) |
| Time from initial treatment to second regimen, median (range) | 21.5 months (2-149 months) |
| Indication for second regimen, N = 44 | |
| Decline in visual acuity | 18 (41) |
| Radiographic | 22 (50) |
| Other | 4 (9) |
| Second treatment regimen, N = 44 | |
| Carboplatin/vincristine | 6 (13) |
| Vinblastine | 12 (27) |
| Bevacizumab/irinotecan | 8 (18) |
| Temozolomide | 4 (9) |
| MEK inhibitor | 5 (11) |
| Other | 9 (20) |
| Duration of follow-up, median (range) | 95 months (13-185 months) |
| Outcome of Interest . | N (%) . |
|---|---|
| Treatment regimens required | |
| Multiple treatment regimens | 45 (44) |
| Single treatment regimen | 58 (56) |
| Number of required regimens | |
| 1 | 58 (56) |
| 2 | 26 (25) |
| 3 | 8 (8) |
| 4 | 7 (7) |
| >=5 | 4 (4) |
| Refractory/relapsed OPG by 2 years, N = 100 | 22 (22) |
| Refractory/relapsed OPG by 5 years, N = 90 | 36 (40) |
| Time from initial treatment to second regimen, median (range) | 21.5 months (2-149 months) |
| Indication for second regimen, N = 44 | |
| Decline in visual acuity | 18 (41) |
| Radiographic | 22 (50) |
| Other | 4 (9) |
| Second treatment regimen, N = 44 | |
| Carboplatin/vincristine | 6 (13) |
| Vinblastine | 12 (27) |
| Bevacizumab/irinotecan | 8 (18) |
| Temozolomide | 4 (9) |
| MEK inhibitor | 5 (11) |
| Other | 9 (20) |
| Duration of follow-up, median (range) | 95 months (13-185 months) |
Abbreviations: MEK, mitogen-activated kinase kinase; OPG, optic pathway glioma; VA, visual acuity.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
